Altimmune (ALT) Reports First Patient Dosing in Phase 1b Clinical Trial of NasoShield

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/19/2026

1. VRNS
2. CRWV
3. JBHT
4. TSLA
5. SCHW
6. GPRK
7. TRV
8. TFC
9. TECHM:IN
10. NVDA

Go back to Altimmune (ALT) Reports First Patient Dosing in Phase 1b Clinical Trial of NasoShield

Pre-Open Stock Movers 06/29: (KNSA) (WKHS) (COTY) Higher; (ICPT) (HRTX) (BYND) Lower (more...)

June 29, 2020 9:31 AM EDT

Today's Pre-Open Stock Movers

Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) 38.4% LOWER; announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA) for obeticholic acid (OCA) for the treatment of fibrosis due to nonalcoholic steatohepatitis (NASH).

Heron Therapeutics, Inc. (Nasdaq: HRTX) 34.5% LOWER; announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on June 26, 2020 regarding its New Drug Application (NDA)... More

Altimmune (ALT) Receives Award from U.S. Department of Defense to Fund Phase 1/2 Clinical Trial of T-COVID in Outpatients with Early COVID-19

June 29, 2020 7:10 AM EDT

Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it was awarded $4.7 million from the U.S. Army Medical Research & Development Command (USAMRDC) to fund its Phase 1/2 clinical trial of T-COVID, an investigational intranasal immune modulator for the treatment of outpatients with early COVID-19. The competitive award was granted by USAMRDC in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium working in partnership with the Department of Defense (DoD). The award is expected to provide Altimmune sufficient funding to cover the entire cost of conducting this clinical trial.

... More

Pre-Open Stock Movers 06/26: (MDCA) (VXRT) (GPS) Higher; (SHIP) (SOLY) (NKE) Lower (more...)

June 26, 2020 9:28 AM EDT

Pre-Open Stock Movers:

MDC Partners Inc. (NASDAQ: MDCA) 146% HIGHER; announced that its Board of Directors has formed a special committee of independent directors to review the preliminary, non-binding proposal made by Stagwell Media LP with respect to a potential business combination between the Company and Stagwell. Mark Penn, Chairman and Chief Executive Officer of the Company, is also the managing partner of Stagwell. The special committee has not reached any conclusion as to the advisability or feasibility of a Potential Transaction.

Vaxart (NASDAQ:... More